Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus: A position statement of the Korean diabetes association

behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Original languageEnglish
Pages (from-to)423-429
Number of pages7
JournalDiabetes and Metabolism Journal
Volume41
Issue number6
DOIs
Publication statusPublished - 2017 Dec 1

    Fingerprint

Keywords

  • Cardiovascular benefit
  • Clinical practice guideline
  • Combination therapy
  • Glucagon-like peptide-1 receptor agonist
  • Hypoglycemia
  • Monotherapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this